help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Orskov, C.
Right arrow Articles by Nielsen, O. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Orskov, C.
Right arrow Articles by Nielsen, O. V.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*GLUCAGON

Endocrinology, Vol 123, 2009-2013, Copyright © 1988 by Endocrine Society

ARTICLES

Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach

C Orskov, JJ Holst and OV Nielsen
Institute of Medical Physiology, Panum Institute, Copenhagen, Denmark.

We studied the effect of truncated glucagon-like peptide-1 [naturally occurring GLP-1; proglucagon-(78-107) amide], a potent insulinotropic peptide from the pig ileum, on endocrine and exocrine secretion of potential gastrointestinal target organs using isolated perfused preparations of the porcine pancreas, antrum, and nonantral part of the stomach. Truncated GLP-1 significantly increased somatostatin secretion from the pancreas at 10(-10) mol/liter and more than doubled the secretion at 10(-9) mol/liter, but had no effect on either somatostatin or gastrin secretion from the antrum or on somatostatin secretion from the nonantral stomach in concentrations up to 10(-8) mol/liter. Insulin secretion from the pancreas (with 7 mmol/liter glucose in the perfusate) increased 2-fold with truncated GLP-1 at 10(-10) mol/liter and almost 5-fold at 10(-9) mol/liter. Pancreatic glucagon secretion was inhibited by 50% at 10(-10) mol/liter and by 70-80% at 10(-9) mol/liter. Full-length GLP-1 [proglucagon-(72-107)] and GLP-2 [proglucagon-(126-159)] had no effect on hormone secretion from any of the perfused organs. It is concluded that truncated GLP-1 may participate in an entero-insular control of pancreatic endocrine secretion.


This article has been cited by other articles:


Home page
 DiabetesHome page
K. Vollmer, J. J. Holst, B. Baller, M. Ellrichmann, M. A. Nauck, W. E. Schmidt, and J. J. Meier
Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance
Diabetes, March 1, 2008; 57(3): 678 - 687.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
J. J. Holst
The Physiology of Glucagon-like Peptide 1
Physiol Rev, October 1, 2007; 87(4): 1409 - 1439.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
K. Raun, P. von Voss, C. F. Gotfredsen, V. Golozoubova, B. Rolin, and L. B. Knudsen
Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not
Diabetes, January 1, 2007; 56(1): 8 - 15.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
R K. Campbell
Rationale for Dipeptidyl Peptidase 4 Inhibitors: A New Class of Oral Agents for the Treatment of Type 2 Diabetes Mellitus
Ann. Pharmacother., January 1, 2007; 41(1): 51 - 60.
[Abstract] [Full Text] [PDF]

Home page
 PhysiologyHome page
E. M Sinclair and D. J. Drucker
Proglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential
Physiology, October 1, 2005; 20(5): 357 - 365.
[Abstract] [Full Text] [PDF]

Home page
 Clin. DiabetesHome page
K. Dungan and J. B. Buse
Glucagon-Like Peptide 1-Based Therapies for Type 2 Diabetes: A Focus on Exenatide
Clin. Diabetes, April 1, 2005; 23(2): 56 - 62.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. Dey, G. M. Lipkind, Y. Rouille, C. Norrbom, J. Stein, C. Zhang, R. Carroll, and D. F. Steiner
Significance of Prohormone Convertase 2, PC2, Mediated Initial Cleavage at the Proglucagon Interdomain Site, Lys70-Arg71, to Generate Glucagon
Endocrinology, February 1, 2005; 146(2): 713 - 727.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. J. Holst and J. Gromada
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Am J Physiol Endocrinol Metab, August 1, 2004; 287(2): E199 - E206.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T. Hansotia, L. L. Baggio, D. Delmeire, S. A. Hinke, Y. Yamada, K. Tsukiyama, Y. Seino, J. J. Holst, F. Schuit, and D.J. Drucker
Double Incretin Receptor Knockout (DIRKO) Mice Reveal an Essential Role for the Enteroinsular Axis in Transducing the Glucoregulatory Actions of DPP-IV Inhibitors
Diabetes, May 1, 2004; 53(5): 1326 - 1335.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
Y. Miura and H. Matsui
Glucagon-like peptide-1 induces a cAMP-dependent increase of [Na+]i associated with insulin secretion in pancreatic {beta}-cells
Am J Physiol Endocrinol Metab, November 1, 2003; 285(5): E1001 - E1009.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. J. Drucker
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Diabetes Care, October 1, 2003; 26(10): 2929 - 2940.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Lopez de Maturana, A. Willshaw, A. Kuntzsch, R. Rudolph, and D. Donnelly
The Isolated N-terminal Domain of the Glucagon-like Peptide-1 (GLP-1) Receptor Binds Exendin Peptides with Much Higher Affinity than GLP-1
J. Biol. Chem., March 14, 2003; 278(12): 10195 - 10200.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
D. J. Drucker
Glucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis
Mol. Endocrinol., February 1, 2003; 17(2): 161 - 171.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. Vilsboll, H. Agerso, T. Krarup, and J. J. Holst
Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects
J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 220 - 224.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
B. Rolin, M. O. Larsen, C. F. Gotfredsen, C. F. Deacon, R. D. Carr, M. Wilken, and L. B. Knudsen
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta -cell mass in diabetic mice
Am J Physiol Endocrinol Metab, October 1, 2002; 283(4): E745 - E752.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. A. Nauck, M. M. Heimesaat, K. Behle, J. J. Holst, M. S. Nauck, R. Ritzel, M. Hufner, and W. H. Schmiegel
Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers
J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1239 - 1246.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M.-B. Toft-Nielsen, M. B. Damholt, S. Madsbad, L. M. Hilsted, T. E. Hughes, B. K. Michelsen, and J. J. Holst
Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients
J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3717 - 3723.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. F. Deacon, P. Danielsen, L. Klarskov, M. Olesen, and J. J. Holst
Dipeptidyl Peptidase IV Inhibition Reduces the Degradation and Clearance of GIP and Potentiates Its Insulinotropic and Antihyperglycemic Effects in Anesthetized Pigs
Diabetes, July 1, 2001; 50(7): 1588 - 1597.
[Abstract] [Full Text] [PDF]

Home page
 Integr. Comp. Biol.Home page
S. Mojsov
Glucagon-like Peptide-1 (GLP-1) and the Control of Glucose Metabolism in Mammals and Teleost Fish
Integr. Comp. Biol., April 1, 2000; 40(2): 246 - 258.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
T. J. Kieffer and J. Francis Habener
The Glucagon-Like Peptides
Endocr. Rev., December 1, 1999; 20(6): 876 - 913.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
E. Naslund, J. Bogefors, S. Skogar, P. Gryback, H. Jacobsson, J. J. Holst, and P. M. Hellstrom
GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans
Am J Physiol Regulatory Integrative Comp Physiol, September 1, 1999; 277(3): R910 - R916.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
A. Wettergren, M. Wojdemann, and J. J. Holst
Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow
Am J Physiol Gastrointest Liver Physiol, November 1, 1998; 275(5): G984 - G992.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L. C. Fung, C. Chisholm, and G. R. Greenberg
Glucagon-Like Peptide-1-(7-36) Amide and Peptide YY Mediate Intraduodenal Fat-Induced Inhibition of Acid Secretion in Dogs
Endocrinology, January 1, 1998; 139(1): 189 - 194.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. A. Nauck, U. Niedereichholz, R. Ettler, J. J. Holst, C. Orskov, R. Ritzel, and W. H. Schmiegel
Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
Am J Physiol Endocrinol Metab, November 1, 1997; 273(5): E981 - E988.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. G. Holz, IV, C. A. Leech, and J. F. Habener
Activation of a cAMP-regulated Ca[IMAGE]-Signaling Pathway in Pancreatic [IMAGE]-Cells by the Insulinotropic Hormone Glucagon-like Peptide-1
J. Biol. Chem., July 28, 1995; 270(30): 17749 - 17757.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
C. F. Deacon, A. Plamboeck, S. Moller, and J. J. Holst
GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion
Am J Physiol Endocrinol Metab, April 1, 2002; 282(4): E873 - E879.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1988 by The Endocrine Society